European Commission issues positive decision for approval of Seroquel XR as an add-on treatment of major depressive disorder.

AstraZeneca has announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy. This decision follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) in Apr 2010. AstraZeneca will now move forward in obtaining local approvals. This is a 30 day process in the 17 member states that took part in the original Mutual …